Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Delafloxacin Compared With Vancomycin + Aztreonam in Patients With Acute Bacterial Skin and Skin Structure Infections
Sponsor: Melinta Therapeutics, Inc.
Listed as NCT01811732, this PHASE3 trial focuses on Skin and Subcutaneous Tissue Bacterial Infections and remains completed. Sponsored by Melinta Therapeutics, Inc., it has been updated 8 times since 2013, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Sep 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Apr 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Melinta Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Anaheim, United States , Barcelona, Spain , Butte, United States , Chemivtsi, Ukraine , Cherkasy, Ukraine , Chula Vista, United States , Daugavpils, Latvia , Dnipropetrovsk, Ukraine , Granada, Spain , Haifa, Israel and 34 more locations